Summary

The aim of the study is to generate additional safety and immunogenicity data to support the
registration of the product in Japan.

Primary objectives:

- To demonstrate the non-inferiority of SP306 versus DT (DT BIK® 0.1mL) vaccine in terms
of diphtheria and tetanus booster response rate (proportion of subjects with booster
responses) and seroprotection rate (percentage of subjects with antitoxin
concentrations ≥0.1 IU/mL) at 28 days (window 28-35 days) after one injection in
Japanese adolescents 11-12 years of age.

- To evaluate the immune response of SP306 against the pertussis antigens PT and FHA in
terms of booster response rate (proportion of subjects with booster responses) at 28
days (window 28-35 days) after one injection in Japanese adolescents 11-12 years of
age.

Secondary objectives:

- To further evaluate the immune response of the study vaccines against diphtheria,
tetanus and pertussis antigens.

- To assess the safety of the study vaccines after one injection in Japanese adolescents
11-12 years of age.

Eligibility Criteria

Male or female participants from 11 years up to 12 years old.

Inclusion Criteria:
- Aged 11 or 12 years and considered healthy on the day of inclusion
- Informed consent form and assent form signed and dated by the parent(s) / legal
representative(s) and the subject respectively
- Completed childhood vaccination against diphtheria, pertussis and tetanus (i.e.,
received 4 doses of Japanese-produced TdaP vaccine), confirmed by checking
immunization records and have not yet undergone additional DT vaccination
- Able to attend all scheduled visits and to comply with all trial procedures
- For female subjects, either pre-menarchal, or post-menarchal with a negative urine
pregnancy test.
Exclusion Criteria:
- Any conditions or diseases which, in the opinion of the Investigator:
- would pose a health risk to the subject
- or might interfere with the ability to participate fully in the study
- or might interfere with evaluation of the vaccine
- or would otherwise make participation inappropriate according to the Investigator's
clinical judgment
- History of diphtheria, tetanus, pertussis, confirmed either clinically,
serologically, or microbiologically
- Suspected or known hypersensitivity to any of the vaccine components or history of a
life threatening reaction to a vaccine containing the same substances of the study
vaccine
- Vaccination in the last 5 years against tetanus, diphtheria, and/or pertussis
- Known or suspected congenital immunodeficiency, or current / previous acquired
immunodeficiency, or current / previous receipt of immunosuppressive therapy such as
anti-cancer chemotherapy or radiation therapy, or current / previous (within the last
6 months) systemic corticosteroid therapy
- Participation in another clinical trial investigating a vaccine, drug, medical
device, or medical procedure in the 4 weeks preceding the trial inclusion
- Planned participation in another clinical trial during the present trial period
- Receipt of blood or blood-derived products in the past 3 months, that might interfere
with assessment of the immune response
- Receipt of any vaccine within the 4 weeks preceding the trial vaccination, except for
influenza vaccination, which may be received at least 2 weeks before the study
vaccine
- Planned receipt of any vaccine during the trial period
- Clinical or known serological evidence of systemic illness including Hepatitis B,
Hepatitis C and/or Human Immunodeficiency Virus (HIV) infection
- At high risk for diphtheria, tetanus or pertussis infection during the trial
- Known pregnancy, or a positive urine pregnancy test
- Currently breastfeeding a child
- Known thrombocytopenia or history of thrombocytopenia
- Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion
- History of acute disseminated encephalomyelitis, encephalopathy, Guillain-Barré
Syndrome (GBS), or autoimmune disease
- Deprived of freedom by an administrative or court order, or in an emergency setting,
or hospitalized involuntarily
- Current alcohol abuse or drug addiction that might interfere with the ability to
comply with trial procedures
- Identified as an employee of an Investigator, a study center, a study-affiliated
vendor, or the Sponsor, with direct or indirect involvement in the proposed study or
other studies under the direction of that Investigator or study center; or identified
as a spouse or child (whether natural or adopted) of such an employee.

Additional Information

Official title

Immunogenicity and Safety of the Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (SP306) Given Intramuscularly Compared to Diphtheria and Tetanus Toxoids Adsorbed (DT) Given Subcutaneously in Japanese Adolescents 11 - 12 Years of Age

Description

Study participants will receive either a single dose of SP306 vaccine intramuscularly or a
dose of DT BIK® vaccine subcutaneously. They will be monitored after vaccination for
immediate adverse events (AEs) solicited injection site and systemic reactions and
unsolicited AEs including serious adverse events throughout the study period, approximately
28 days (+7 days).

Trial information was received from ClinicalTrials.gov and was last updated in January 2015.